Under the background of multi-point outbreak of China’s epidemic and the “opening” of antigen self-test products, covid-19 antigen detection concept unit became a “good start” this week.
At the opening of trading yesterday (March 14), the share prices of several listed companies whose covid-19 antigen self-test products were approved for listing rose one after another. As of the closing of the day, Guangzhou Wondfo Biotech Co.Ltd(300482) ( Guangzhou Wondfo Biotech Co.Ltd(300482) , SZ; yesterday’s closing price of 61.98 yuan) rose 3.71%, Bgi Genomics Co.Ltd(300676) ( Bgi Genomics Co.Ltd(300676) , SZ; yesterday’s closing price of 98.32 yuan) rose 9.98%, and Nanjing Vazyme Biotech Co.Ltd(688105) ( Nanjing Vazyme Biotech Co.Ltd(688105) , SH; yesterday’s closing price of 120.74 yuan) rose 13.59%.
At the same time, yesterday morning, Beijing Hotgen Biotech Co.Ltd(688068) ( Beijing Hotgen Biotech Co.Ltd(688068) , SH; yesterday’s closing price of 200.49 yuan) and Lepu Medical Technology (Beijing) Co.Ltd(300003) ( Lepu Medical Technology (Beijing) Co.Ltd(300003) , SZ; yesterday’s closing price of 21.61 yuan) also successively announced that covid-19 antigen self-test products were approved for listing, and the stock price rose strongly.
The reporter of the daily economic news called the Beijing Hotgen Biotech Co.Ltd(688068) securities department. The other party said that the company would actively plan and arrange production according to the existing production capacity. The company has signed a strategic cooperation agreement with Meinian Onehealth Healthcare Holdings Co.Ltd(002044) group, and Meinian Onehealth Healthcare Holdings Co.Ltd(002044) group will become the core partner of the sales channel of Beijing Hotgen Biotech Co.Ltd(688068) covid-19 antigen detection products. In addition, the company is also building cooperative relations with other large pharmaceutical enterprises and primary retail, and some network sales channels are also being built.
For the price concerned by consumers, the official said that it should be considered according to several factors, including the development speed of the epidemic, the guidance of relevant policies in China, the price of raw materials, etc. At present, the ex factory price of the company’s products has not been determined.
“In fact, our previous production has not stopped, and we have been in intense production… As for the product launch plan of various retail channels, it will take some time.” The staff told reporters that the company has a wide distribution throughout the country, especially in the north. At present, the company is paying attention to and promoting the sales distribution throughout the country. In the future, it will promote products based on the existing sales channels throughout the country, respond to the national call and fight the epidemic.
Lepu Medical Technology (Beijing) Co.Ltd(300003) the person from the Securities Department told reporters that the approved antigen self-test products were originally mainly sold overseas and have not been sold in China. Therefore, the sales channel, sales price, delivery area and other information of the products have not been determined yet. It will take some time to consider, but they will be listed as soon as possible.
